{"id":"placebo-adalimumab-placebo-mtx","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"TNF-alpha is a cytokine that plays a key role in systemic inflammation, and its blockade has been shown to be effective in treating various autoimmune diseases. By binding to TNF-alpha, adalimumab prevents the activation of immune cells and the release of pro-inflammatory cytokines, leading to a reduction in inflammation and disease symptoms.","oneSentence":"Adalimumab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby reducing inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:17.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"}]},"trialDetails":[{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT01716039","phase":"PHASE2","title":"Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)","status":"TERMINATED","sponsor":"Alimentiv Inc.","startDate":"2013-06","conditions":"Ulcerative Colitis","enrollment":22},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT02983227","phase":"PHASE2","title":"A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-11-30","conditions":"Rheumatoid Arthritis","enrollment":496},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT04154852","phase":"PHASE2","title":"ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-06","conditions":"Oligoarthritis","enrollment":22},{"nctId":"NCT01710358","phase":"PHASE3","title":"A Study in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":1307},{"nctId":"NCT03217734","phase":"PHASE2, PHASE3","title":"MAP Study: Methotrexate and Adalimumab in Psoriasis","status":"COMPLETED","sponsor":"Jeffrey J Crowley MD","startDate":"2017-04-10","conditions":"Psoriasis","enrollment":56},{"nctId":"NCT01500278","phase":"PHASE4","title":"Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2011-12","conditions":"Rheumatoid Arthritis","enrollment":915},{"nctId":"NCT02150473","phase":"PHASE3","title":"The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients","status":"TERMINATED","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2014-10","conditions":"Rheumatoid Arthritis","enrollment":21},{"nctId":"NCT01251614","phase":"PHASE3","title":"A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-12","conditions":"Plaque Psoriasis","enrollment":114},{"nctId":"NCT02349451","phase":"PHASE2","title":"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-28","conditions":"Psoriatic Arthritis","enrollment":240},{"nctId":"NCT01764997","phase":"PHASE3","title":"An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate","status":"TERMINATED","sponsor":"Sanofi","startDate":"2013-04","conditions":"Rheumatoid Arthritis","enrollment":776},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT00195663","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2000-12","conditions":"Early Rheumatoid Arthritis","enrollment":799},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032},{"nctId":"NCT00195702","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-02","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00048542","phase":"PHASE3","title":"Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Arthritis, Juvenile Idiopathic","enrollment":171},{"nctId":"NCT00235820","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-07","conditions":"Psoriasis","enrollment":271}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["placebo"],"phase":"phase_3","status":"active","brandName":"placebo adalimumab, placebo MTX","genericName":"placebo adalimumab, placebo MTX","companyName":"Abbott","companyId":"abbott","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and thereby reducing inflammation. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}